MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

Search

Gimv NV

Cerrado

SectorFinanzas

42.2 -0.12

Resumen

Variación precio

24h

Actual

Mínimo

42.05

Máximo

42.45

Métricas clave

By Trading Economics

Ingresos

145M

Ventas

-74M

114M

P/B

Media del Sector

5.663

25.916

BPA

2.45

Rentabilidad por dividendo

6.05

Margen de beneficio

722.337

Empleados

94

EBITDA

-70M

76M

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

6.05%

3.70%

Próximas Ganancias

30 sept 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-52M

1.6B

Apertura anterior

42.32

Cierre anterior

42.2

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

110 / 536 Clasificación en Finance

Gimv NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 21:42 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 ago 2025, 21:21 UTC

Ganancias
Principales Movimientos del Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 ago 2025, 20:45 UTC

Ganancias

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 ago 2025, 23:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 ago 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 ago 2025, 23:28 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 ago 2025, 23:28 UTC

Charlas de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 ago 2025, 21:30 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 21:21 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 ago 2025, 21:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 20:25 UTC

Charlas de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss $938M >RIG

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss/Shr $1.06 >RIG

4 ago 2025, 20:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 ago 2025, 20:15 UTC

Ganancias

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 ago 2025, 20:13 UTC

Ganancias

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 ago 2025, 20:09 UTC

Ganancias

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 ago 2025, 20:06 UTC

Ganancias

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 ago 2025, 19:41 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 ago 2025, 19:28 UTC

Charlas de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 ago 2025, 19:07 UTC

Charlas de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 ago 2025, 18:27 UTC

Charlas de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparación entre iguales

Cambio de precio

Gimv NV Esperado

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

110 / 536 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Gimv NV

Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer, connected consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. Within consumer, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services-based companies. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource efficient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software and services harnessing the flexibility of the cloud, smart data management and advanced c